At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
[¹⁴C]-LY3502970drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Disposition of [¹⁴C]-LY3502970 Following Oral Administration in Healthy Male Participants
In Brief
A Phase 1 clinical trial evaluating [¹⁴C]-LY3502970 for Healthy. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to 8 weeks (maximum).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionJul 2021
TodayJul 2026
First PostedDec 23, 2020
Enrollment StartMar 29, 2021
Primary CompletionJul 3, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.5 years ago
Interventions
[¹⁴C]-LY3502970drug
Administered orally.